TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients with type 2 diabetes mellitus~* 6.5% ≤ HbA1c \< 9.0%~* Stopped treatment of sulfonylurea and biguanide for more than 8 weeks~* Stopped treatment of other anti-diabetic agents for more than 12 weeks~* 16 kg/m2 ≤ body mass index \< 30 kg/m2~Exclusion Criteria:~* Fasting glucose ≥ 200 mg/dL~* Required insulin therapy~* Patients with neuropathy, retinopathy or renopathy~* Contraindicated for mitiglinide or sitagliptin

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: ACTIVE_COMPARATOR): None
- Mitiglinide (Type: ACTIVE_COMPARATOR): None
- Sitagliptin + Mitiglinide (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Suspected pulmonary tuberculosis with acid-fast bacilli in a stained smear of expectorated or induced sputum.~2. Willingness to have HIV testing performed, if HIV serostatus is not known or if the last documented negative HIV test was more than 3 months prior to enrollment.~3. 5 (five) or fewer days of multidrug therapy for tuberculosis disease in the 6 months preceding initiation of study drugs.~4. 7 (seven) or fewer days of fluoroquinolone therapy in the 30 days preceding initiation of study drugs.~5. Age \>= 18 years~6. Karnofsky score of at least 60 (requires occasional assistance but is able to care for most of his/her needs; see Appendix B)~7. Signed informed consent~8. Women of child-bearing potential must agree to practice an adequate (barrier) method of birth control or to abstain from heterosexual intercourse during study therapy.~9. Laboratory parameters done within 14 days prior to, enrollment:~   * Serum or plasma alanine aminotransferase (ALT) activity ≤ 3 times the upper limit of normal~  * Serum or plasma total bilirubin level ≤ 2.5 times the upper limit of normal~  * Serum or plasma creatinine level ≤ 2 times the upper limit of normal~  * Complete blood count with hemoglobin level of at least 7.0 g/dL~  * Complete blood count with platelet count of at least 100,000/mm3~  * Negative pregnancy test (women of childbearing potential)~Exclusion Criteria:~1. Pregnant or breast-feeding~2. Known intolerance or allergy to any of the study drugs~3. Concomitant disorders or conditions for which isoniazid (INH), rifamycins, pyrazinamide (PZA), or ethambutol (EMB) are contraindicated. These include severe hepatic damage, acute liver disease of any cause, and acute uncontrolled gouty arthritis.~4. Current or planned therapy, during the intensive phase of TB therapy, with combination antiretroviral therapy for HIV, or with cyclosporine or tacrolimus. Cyclosporine and tacrolimus have unacceptable interactions with rifamycins.~5. Pulmonary silicosis~6. Central nervous system TB~7. Weight \< 40 kg or \> 85 kg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): rifampin, isoniazid, pyrazinamide, ethambutol
- 2 (Type: EXPERIMENTAL): rifapentine 10 mg/kg, isoniazid, pyrazinamide, ethambutol
- 3 (Type: EXPERIMENTAL): rifapentine 15 mg/kg, isoniazid, pyrazinamide, ethambutol
- 4 (Type: EXPERIMENTAL): rifapentine 20 mg/kg, isoniazid, pyrazinamide, ethambutol

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Wearable Robotic Assistance on Gait

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DEVICE_FEASIBILITY
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 5 and 35 years old, inclusive.~* Either a healthy volunteer or a diagnosis of a neurologically-based walking disorder due to stroke, spinal cord injury, Parkinson's disease, or cerebral palsy.~* Must be able to understand and follow simple directions based on parent report and clinical observation during the history and physical examination.~* Able to provide verbal assent, if appropriate. If the participant is non-verbal, parental interpretation of gesticulation for assent will be used.~* The ability to read and understand English.~* Able to walk at least 30 feet with or without a walking aid (GMFCS Level I-III for individuals with cerebral palsy)~Exclusion Criteria:~• Any neurological, musculoskeletal or cardiorespiratory injury, health condition ( including pregnancy), or diagnosis other than stroke, spinal cord injury, Parkinson's disease or cerebral palsy that would affect the ability to walk as directed for short periods of time.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- Gait Training with Exoskeleton Assistance (Type: EXPERIMENTAL): Gait training with ankle exoskeleton assistance. All participants received high frequency gait training followed by a washout period then low frequency gait training.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Survey on Efficacy and Safety in Patients With Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women aged 20 to \< 50 years~* Subjects with a chocolate cyst of the ovary measuring 3 cm in diameter on transvaginal ultrasonography at patient enrollment~* Subjects with a menstrual cycle of 25 to 38 days who ovulate and are confirmed to have normal menstruation at patient enrollment~Exclusion Criteria:~* Subjects who used GnRH agonists within 6 months before patient enrollment~* Subjects who utilized hormone preparations containing corpus luteum hormone or estrogen as an active ingredient, low-dose contraceptive pills, middle-dose contraceptive pills, testosterone derivatives, or herbal products indicated for endometriosis within 3 months before patient enrollment~* Subjects who received surgical treatment for endometriosis such as transvaginal alcohol fixation, laparotomy or laparoscopic surgery within 2 months before patient enrollment~* Subjects who are pregnant or may possibly be pregnant at patient enrollment~* Subjects who are in breast feeding at patient enrollment~* Subjects who are determined by the investigator/subinvestigator to be not suitable for the subjects of the survey because of other reasons~* Subjects with liver disorder or liver disease~* Subjects with known hypersensitivity to the active substance or to any of the excipients~* Subjects with known or suspected progestogen dependent neoplasms (e.g. meningioma)~* Subjects with undiagnosed vaginal bleeding~* Subjects with a past or current history of heart or kidney disease~* Subjects with porphyria~* Subjects with depression~* Subjects with abnormal liver function values caused by acute or chronic liver disease~* Subjects with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucosegalactose malabsorption

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Dydrogesterone (Type: None): Dydrogesterone 20 mg (4 tablets) per day should be orally administered in 2 divided doses (in the morning and evening). It should be administered for 21 days; dosage starts on the 5th day of each menstrual cycle until 25th day. The administration period will be from the start of Duphaston treatment (cycle 1) to cycle 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Intravenous and Oral Iron in Postoperative Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years of age) were recruited at the scheduled preoperative visit (21 to 30 days prior surgery knee replacement). Anaemia (Hb \<12 g/dL) and/or iron deficiency (TSAT \<20%) the day after surgery~Exclusion Criteria:~* Patients with known hypersensitivity or contraindications to iron, liver insufficiency (aspartate aminotransferase or alanine aminotransferase \>60 IU/L), bronchial asthma, presence of acute or chronic infection, severe heart disease, significant history of allergies (rash, etc.) or anti-anaemia treatment within 15 days prior to surgery were excluded from participation. Also pregnant or nursing women were excluded (negative pregnancy urine test within 7 days prior first study treatment or amenorrhoea for at least 12 months).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric carboxymaltose (Type: EXPERIMENTAL): Ferric carboxymaltose (Ferinject®, Vifor-France) was given as a single i.v. dose to correct the total iron deficit calculated by the Ganzoni formula (total iron deficit \[mg\] = 2.4 x patient's weight \[kg\] x (target Hb \[13 g/dL\] - current Hb \[g/dL\]) + 500 \[mg iron stores\]
- Ferrous glycine sulphate (Type: ACTIVE_COMPARATOR): Ferrous glycine sulphate (Ferbisol-Bial Industrial Farmacéutica, Spain) was given as a once daily oral dose of 100 mg iron from the day of discharge (Day 7) to the rehabilitation visit 30 days after surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Montelukast in Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute Asthma exacerbation requiring hospitalisation~Exclusion Criteria:~* Smoking history greater than or equal to 10 pack years~* Presenting PEFR greater than or equal to 75% predicted / best~* Failure to demonstrate greater than or equal to 15% variability in PEFR or FEV during the study~* Any significant and active pulmonary pathology other than asthma~* Pregnancy or breastfeeding~* Intended pregnancy or inability to take adequate precautions against conception~* Patient already on Montelukast~* Patient already on Phenobarbitone~* Patient already on Rifampicin~* Patient already on Phenytoin~* Chronic airflow limitation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): 1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study of VX-770 in Cystic Fibrosis Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants who have completed the assigned study treatment in Study 102 or Study 103~2. Participants who are females of childbearing potential must have a negative urine pregnancy test on Day 1 (first dose of VX-770)~3. Participants who are able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned, as judged by the investigator~4. Participants of child bearing potential and who are sexually active must meet the contraception requirements~5. Participants must sign the informed consent form (ICF), and where appropriate, assent must be obtained~Exclusion Criteria:~1. Participants with a history of any illness or condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject~2. Participants with a history of study treatment intolerance as observed in their previous VX-770 study that, in the opinion of the investigator, might pose an additional risk in administering study drug to the subject~3. Participants who are pregnant, planning a pregnancy, breast-feeding, or not willing to follow contraception requirements~4. Participants taking any inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4), including certain herbal medications (for example, St. John's Wort) and grapefruit/grapefruit juice

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VX-770 (Type: EXPERIMENTAL): VX-770 (ivacaftor) 150 milligram (mg) tablet orally twice daily (q12h).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Acthar on Everyday Life of Participants With Severe Keratitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Has severe or recalcitrant keratitis~* Did not respond to, or tolerate, treatment with topical cyclosporine, Lifitegrast, or any immunosuppressant to treat keratitis~* If able to reproduce, agrees to use 2 forms of effective contraception with a partner of the opposite sex for the duration of the study (through Visit 6)~* Has normal eyelids, and protocol-defined physical and medical eye attributes~* Agrees to avoid wearing contact lenses during the trial~Exclusion Criteria:~* Is pregnant or breast-feeding~* Is defined as vulnerable, or is employed by, or related to anyone involved in the study~* Has a medical condition or history that might, per protocol or in the opinion of the investigator, compromise the participant's safety or study analysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All participants (Type: EXPERIMENTAL): Participants receive:~* a shot of Acthar (80 units) under the skin twice a week for 12 weeks~* a shot of Acthar (40 units) twice a week for 2 weeks~* a shot of Acthar (40 units) once a week for 2 more weeks~At each visit they will have medical tests and answer questions about their symptoms.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of Patient Preoperative Prep

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects of any race.~* Subjects in good health.~* Minimum skin flora baseline requirements on abdomen and groin.~* Skin free of tattoos, dermatoses, abrasions, cuts, lesions, or other skin disorder near or on the applicable test area.~Exclusion Criteria:~* Topical or systemic antimicrobial exposure within 14 days prior to screening and treatment days, including antibiotics.~* Subjects with a history of skin sensitivity, skin allergies, or skin cancer.~* Subjects who are pregnant, attempting pregnancy, or nursing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- ZP (70% IPA) (Type: EXPERIMENTAL): Isopropyl alcohol (IPA) 70%
- ChloraPrep (Type: ACTIVE_COMPARATOR): Chlorhexidine gluconate (CHG) 2% / Isopropyl alcohol (IPA) 70%
- ZP Vehicle (Type: PLACEBO_COMPARATOR): ZP without IPA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)~Exclusion Criteria:~* Malabsorption, renal or liver disease, treatment with steroids

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Glutamine+Sitagliptin (Type: EXPERIMENTAL): Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
- Glutamine+Placebo (Type: PLACEBO_COMPARATOR): Glutamine 30 g/d (15 g with breakfast and dinner) + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of ulcerative colitis and in remission for at least 1 month.~* Greater than 18 years of age.~Exclusion Criteria:~* Allergy/intolerance to aspirin, mesalamine or other salicylates.~* Prior bowel surgery other than appendectomy.~* Pregnancy, at risk of pregnancy or lactating.~* HIV or hepatitis B or C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 (Type: PLACEBO_COMPARATOR): Placebo
- 1 (Type: ACTIVE_COMPARATOR): Granulated mesalamine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of a Eye Drop for Eye Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least 10 years of age~* positive history of ocular allergies~* positive skin test reaction to allergens.~Exclusion Criteria:~* known allergy, contraindication, or sensitivities to the use of any of the study medication(s) or their components~* ocular surgical intervention within three (3) months prior to visit 1 or during the study~* known history of retinal detachment, diabetic retinopathy, or progressive retinal disease, or glaucoma~* any other significant illness

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- alcaftadine ophthalmic solution (Type: EXPERIMENTAL): active treatment: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).
- inactive ophthalmic solution vehicle (Type: PLACEBO_COMPARATOR): Placebo, vehicle: administered as a single one-drop dose in each eye at each visit (Day 0 and Day 14).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Premedication in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Normotensive~* Hypertension with stage 1 or 2~* Scheduled for myomectomy or hysterectomy operation~* Aged 40-60~* ASA I or II~* BMI is under 30 kg/m2~Exclusion Criteria:~* Untreated hypertension~* Users of ACE inhibitors as antihypertensive therapy~* History of severe cardiovascular disease, renal disease, diabetes mellitus, cerebrovascular disease~* An allergy to study drugs~* Difficult airway~* If the time more than fifteen minutes between the start of surgery and the induction~* If necessary blood transfusion was required

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group HD (Type: ACTIVE_COMPARATOR): Dexmedetomidine was administered 0.5 µg.kg-1 in hypertensive patient
- Group ND (Type: SHAM_COMPARATOR): Dexmedetomidine was administered 0.5 µg.kg-1 in normotensive patient
- Group HM (Type: ACTIVE_COMPARATOR): Midazolam was administered 0.025 mg. kg-1 in hypertensive patient.
- Group NM (Type: SHAM_COMPARATOR): Midazolam was administered 0.025 mg. kg-1 in normotensive patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age above 18 years.~* Signed and dated written informed consent before the start of specific protocol procedures.~* ECOG PS 0-1~* Histologically/cytologically confirmed stage IV uveal melanoma~* Measurable disease by computed tomography (CT) or Magnetic Resonance Imaging (MRI) per RECIST 1.1 criteria~* Any number of prior therapies (including none), with the exception of anticancer immunotherapy~Exclusion Criteria:~* Active brain metastases (symptomatic and/or requiring corticosteroids) or leptomeningeal metastases~* Previous treatment with anticancer immunotherapy~* Pregnant or nursing (lactating) women~* Medical, psychiatric, cognitive or other conditions that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study~* Active autoimmune disease~* Immune deficiency or treatment with systemic corticosteroids~* Use of other investigational drugs (drugs not marketed for any indication) within 28 days before study drug administration~* Life expectancy of less than 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pembrolizumab and Entinostat (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete